TNFRSF8 and post-transplant lymphoproliferative disease: Clinical studies, such as the one conducted by Harker-Murray et al. (2023), have shown that BV, alone or in combination with other agents like nivolumab and bendamustine, can lead to significant and durable responses in patients with CD30-positive lymphomas, including PTLD [61,62,63,64].